为捍卫自家核心产品的专利保护期，创新药企云顶新耀（HK01952，股价44.62港元，市值157.75亿港元）在官方微信公众号上主动"开火"。 12月23日，云顶新耀发布声明称："近期，我司注意到，有针对我司上市许可产品布地奈德肠溶胶囊（耐赋康）的仿制药品的上市许可获得批准。" 云顶新耀方面认为，耐赋康的相关技术在中国受到专利保护，该专利目前处于有效状态，其专利权有效期直至2029年5月7日届满。针对任何涉嫌违反上述规 定及承诺的侵权行为，云顶新耀称保留依法采取一切后续行动的权利。 图片来源：云顶新耀微信公众号 据《每日经济新闻》记者（以下简称"每经记者"）检索，12月22日，国家药品监督管理局官网曾发布药品批准证明文件送达信息，其中海南合瑞制药股份有 限公司（以下简称"海南合瑞"）的布地奈德肠溶胶囊（国药准字H20256302）显示已于12月16日得到批准。 12月24日晚间，每经记者联系到海南合瑞董事长钟正明，他对此回复称："目前我们正在跟相关专业的法律人士进行咨询和沟通，是否侵权关键还是要看技 术方案是否落入对方专利权保护的范围。（布地奈德肠溶胶囊）上市销售与否，我们现在还没有做最后的决定。" 耐赋康首 ...

Core Points - The Shanghai Municipal Medical Procurement Management Office has suspended the procurement qualifications of certain drugs, including indobufen tablets produced by Shandong Modern Pharmaceutical Technology Co., Ltd due to patent disputes [1][2] - A total of seven companies have been suspended from procuring indobufen tablets since 2024, indicating a significant impact on the market [2][3] Industry Overview - Indobufen tablets, a new type of antiplatelet drug, were first developed by Farmitalia Carlo Erba in Italy and have become a substitute for patients intolerant to aspirin due to their lower side effects [2] - The sales of indobufen tablets have seen substantial growth, with sales reaching over 1 billion yuan in 2022 and projected to exceed 1.6 billion yuan in 2024, reflecting an 18.12% year-on-year increase [3] Patent and Legal Issues - The core patent for indobufen, covering specific crystal forms and their preparation methods, was granted to a subsidiary of Huadong Medicine, which has initiated extensive legal actions against other companies for patent infringement [4] - Indobufen tablets were excluded from the 11th batch of national procurement due to high patent infringement risks, despite meeting procurement conditions [5]